Literature DB >> 20128632

Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas.

J Cao1, J P Lin, L X Yang, K Chen, Z S Huang.   

Abstract

Craniopharyngiomas are rare, histologically benign, non-neuroepithelial epithelial tumors arising from the sellar region, the molecular pathogenesis of CPs is yet not understood. The aim of the present study was to assess expression of aberrant beta-catenin and impaired p63 in 66 craniopharyngiomas included 51 adamantinomatous craniopharyngiomas and 15 squamous papillary craniopharyngiomas. On immunohistochemistry, 47 out of 51 adamantinomatous craniopharyngiomas, but not squamous papillary craniopharyngiomas, showed strong nuclear/cytoplasmic expression for beta-catenin predominantly in compactly cohesive epithelial cells within the whorl-like arrays where ki-67 was almost absent and rarely in palisaded cells where ki-67 was mainly present. P63 overexpression was observed in 45 out of 51 adamantinomatous craniopharyngiomas and 14 out of 15 squamous papillary craniopharyngiomas. P63 stained not only in the nuclei of basal layer cells but also within the whorl-like arrays in adamantinomatous craniopharyngiomas and uniformly in squamous papillary craniopharyngiomas. Using quantitative real time polymerase chain reaction techniques to correlate p63 protein expression with p63 mRNA levels, TAp63 isoforms mRNA was reduced, whereas DeltaNp63 mRNA elevated at levels in 5 snap frozen tissue samples with multiple large p63 positive cell clusters compared with normal tissues. In conclusion, the present study confirmed that the two variants of CPs have genetically not only distinctive but also common feature. It demonstrated that cytoplasm/nuclear beta-catenin accumulation is an exclusively characteristic morphology of adaCPs. P63 immunohistochemical overexpression were found in both adaCPs and spCPs variant when analyzed in the same study. Taken together, the impaired p63 expression may be attributed to elevated DeltaNp63 mRNA and reduced TAp63mRNA in CPs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20128632     DOI: 10.3109/02688690903576237

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  10 in total

Review 1.  Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.

Authors:  Ruth Prieto; José M Pascual
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

2.  [The 2017 WHO classification of pituitary tumors].

Authors:  Wolfgang Saeger
Journal:  Pathologe       Date:  2021-04-20       Impact factor: 1.011

Review 3.  Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review.

Authors:  Josephine R Coury; Brittany N Davis; Christoforos P Koumas; Giovanna S Manzano; Amir R Dehdashti
Journal:  Neurosurg Rev       Date:  2018-04-17       Impact factor: 3.042

4.  Disease control after reduced volume conformal and intensity modulated radiation therapy for childhood craniopharyngioma.

Authors:  Thomas E Merchant; Larry E Kun; Chia-Ho Hua; Shengjie Wu; Xiaoping Xiong; Robert A Sanford; Frederick A Boop
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-11       Impact factor: 7.038

5.  The Wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis.

Authors:  Veronica Preda; Sarah J Larkin; Niki Karavitaki; Olaf Ansorge; Ashley B Grossman
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

6.  Identification of targets for rational pharmacological therapy in childhood craniopharyngioma.

Authors:  Jacob M Gump; Andrew M Donson; Diane K Birks; Vladimir M Amani; Karun K Rao; Andrea M Griesinger; B K Kleinschmidt-DeMasters; James M Johnston; Richard C E Anderson; Amy Rosenfeld; Michael Handler; Lia Gore; Nicholas Foreman; Todd C Hankinson
Journal:  Acta Neuropathol Commun       Date:  2015-05-21       Impact factor: 7.801

7.  Ki67 as a prognostic factor of craniopharyngioma's recurrence in paediatric population.

Authors:  Elżbieta Moszczyńska; Monika Prokop-Piotrkowska; Agnieszka Bogusz-Wójcik; Wiesława Grajkowska; Sylwia Szymańska; Mieczysław Szalecki
Journal:  Childs Nerv Syst       Date:  2020-02-07       Impact factor: 1.475

8.  Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of β-amyloid.

Authors:  Yilamujiang Ainiwan; Yiguang Chen; Chaofu Mao; Junxiang Peng; Siyuan Chen; Songtao Wei; Songtao Qi; Jun Pan
Journal:  J Neuroinflammation       Date:  2022-05-07       Impact factor: 9.587

9.  Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.

Authors:  John R Apps; Gabriela Carreno; Jose Mario Gonzalez-Meljem; Scott Haston; Romain Guiho; Julie E Cooper; Saba Manshaei; Nital Jani; Annett Hölsken; Benedetta Pettorini; Robert J Beynon; Deborah M Simpson; Helen C Fraser; Ying Hong; Shirleen Hallang; Thomas J Stone; Alex Virasami; Andrew M Donson; David Jones; Kristian Aquilina; Helen Spoudeas; Abhijit R Joshi; Richard Grundy; Lisa C D Storer; Márta Korbonits; David A Hilton; Kyoko Tossell; Selvam Thavaraj; Mark A Ungless; Jesus Gil; Rolf Buslei; Todd Hankinson; Darren Hargrave; Colin Goding; Cynthia L Andoniadou; Paul Brogan; Thomas S Jacques; Hywel J Williams; Juan Pedro Martinez-Barbera
Journal:  Acta Neuropathol       Date:  2018-03-14       Impact factor: 17.088

Review 10.  Current Advances in the Management of Adult Craniopharyngiomas.

Authors:  Montserrat Lara-Velazquez; Yusuf Mehkri; Eric Panther; Jairo Hernandez; Dinesh Rao; Peter Fiester; Raafat Makary; Michael Rutenberg; Daryoush Tavanaiepour; Gazanfar Rahmathulla
Journal:  Curr Oncol       Date:  2022-03-04       Impact factor: 3.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.